CJC-1295 + Ipamorelin vs Ipamorelin
CJC-1295 + Ipamorelin and Ipamorelin are studied in overlapping research areas, which is why they are frequently compared. This is a neutral side-by-side reference drawn from published preclinical literature and laboratory handling data.
How they actually differ
Comparing the two: CJC-1295 + Ipamorelin is combination — ghrh(1-29) analogue plus selective ghrelin-receptor agonist, while Ipamorelin is synthetic pentapeptide gh secretagogue (ghrelin-receptor agonist) — different molecular classes with different handling consequences; their leading degradation routes differ (independent degradation of the two components at different rates, which is the defining stability characteristic of any blend. for CJC-1295 + Ipamorelin, c-terminal amide hydrolysis over long solution storage. for Ipamorelin), so the storage precautions that matter are not the same; their practical working windows differ once reconstituted. The sections below set out each in full.
CJC-1295 + Ipamorelin — origin
This is a two-compound blend studied for complementary mechanisms rather than a single molecule. CJC-1295 is a modified GHRH(1-29) fragment with four amino-acid substitutions that resist enzymatic degradation. Ipamorelin is a pentapeptide ghrelin-receptor agonist notable for its selectivity — it was specifically developed to stimulate GH release without the cortisol and prolactin effects of earlier secretagogues like GHRP-6.
Ipamorelin — origin
Ipamorelin (Aib-His-D-2-Nal-D-Phe-Lys-NH2) is a pentapeptide ghrelin-receptor agonist. It was characterised as the first highly selective growth-hormone secretagogue — prompting GH release with minimal effect on cortisol, prolactin or appetite signalling, which is the property that keeps it in the research literature.
CJC-1295 + Ipamorelin research themes
GHRH-receptor and ghrelin-receptor agonism act through different mechanisms, which is the rationale for pairing them.
Developed specifically for GH release with minimal cortisol and prolactin effects — its defining pharmacological feature.
Studied for effects on the pattern of GH secretion rather than continuous elevation.
A common endpoint in the preclinical literature for GH-axis compounds.
Ipamorelin research themes
Studied as a selective GHS-R agonist that releases GH with little effect on cortisol, prolactin or ACTH — the feature that distinguishes it from earlier GHRPs.
Examined for the shape and timing of growth-hormone release in research models.
Frequently combined with GHRH analogues such as CJC-1295 to study two GH-release pathways at once.
CJC-1295 + Ipamorelin handling
- Confirm whether the labelled mass is total blend mass or per-component before calculating concentration.
- Reconstitute the full vial rather than attempting to subdivide dry material — the two components will not partition evenly in powder form.
- Protect from light and refrigerate.
Ipamorelin handling
- Reach room temperature before opening.
- Swirl to dissolve; the peptide clears in seconds.
- Label aliquots with reconstitution date and diluent.
Both third-party tested
Every Popular Peptides batch of CJC-1295 + Ipamorelin and Ipamorelin is independently tested by HPLC and LC-MS with a published Certificate of Analysis. Enter a lot number to pull the COA for a specific vial.
CJC-1295 + Ipamorelin reference
Related comparisons
CJC-1295 + Ipamorelin and Ipamorelin are supplied strictly as research chemicals for in-vitro laboratory and research use only. They are not intended for human or animal consumption, diagnostic, or therapeutic use. This comparison summarizes published preclinical literature and laboratory handling data; it is not medical advice, not a claim of efficacy, and not usage guidance.